Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

NCT04672564 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

93

Enrollment

INDUSTRY

Sponsor class

Stopped sponsor strategy change

Conditions

Coronavirus Disease 2019

Interventions

DRUG: Carrimycin
DRUG: Placebo

Sponsor

Shenyang Tonglian Group CO., Ltd